Nucleoside analogue DNMT inhibitors, such as 5-azacytidine (Vidaza) and 5-aza-2′-deoxycytidine (Dacogen, decitabine), have been approved by FDA as demethylating agents to treat myelodysplastic syndrome. The gene discussed is DNMT1; the disease is myelodysplastic syndrome.